First Amendment
This article was originally published in The Gray Sheet
Executive Summary
FDA assures Sen. Jack Reed (D-R.I.) it will grant full public participation during its upcoming review of the relationship between First Amendment case law and the agency's commercial speech restrictions. FDA responds Aug. 12 to a July letter from the senator questioning the agency's methods of notifying stakeholders of the review. The letter seeks congressional preview of further actions...